

Franco Trevisani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5455583/publications.pdf>

Version: 2024-02-01

135
papers

8,428
citations

44066
48
h-index

48312
88
g-index

136
all docs

136
docs citations

136
times ranked

7797
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002â€“2033: the ITA.LI.CA database. <i>Gut</i> , 2023, 72, 141-152.	12.1	57
2	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. <i>Gut</i> , 2022, 71, 593-604.	12.1	62
3	Surveillance for hepatocellular carcinoma with a 3-months interval in â€œextremely high-riskâ€œpatients does not further improve survival. <i>Digestive and Liver Disease</i> , 2022, 54, 927-936.	0.9	4
4	Treatment allocation in patients with hepatocellular carcinoma: Need for a paradigm shift?. <i>Liver Cancer International</i> , 2022, 3, 34-36.	1.3	7
5	Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2022, 275, 743-752.	4.2	24
6	Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment. <i>Frontiers in Oncology</i> , 2022, 12, 822507.	2.8	5
7	Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2022, 54, 1215-1221.	0.9	3
8	Monofocal hepatocellular carcinoma: How much does size matter?. <i>Liver International</i> , 2021, 41, 396-407.	3.9	10
9	The changing scenario of hepatocellular carcinoma in Italy: an update. <i>Liver International</i> , 2021, 41, 585-597.	3.9	69
10	Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00286.	2.5	15
11	Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Liver Cancer</i> , 2021, 10, 126-136.	7.7	6
12	Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 370-379.	7.7	31
13	Identification of Clinical Phenotypes and Related Survival in Patients with Large HCCs. <i>Cancers</i> , 2021, 13, 592.	3.7	5
14	Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients. <i>Cancers</i> , 2021, 13, 897.	3.7	9
15	Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter. <i>International Journal of Biological Markers</i> , 2021, 36, 54-61.	1.8	8
16	Liver Resection for Patients with Intermediate Stage Hepatocellular Carcinoma: Beyond Rigid Staging Systems Towards a More Personalized Therapeutic Approach. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1078-1079.	1.7	1
17	Pattern of macrovascular invasion in hepatocellular carcinoma. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13542.	3.4	18
18	Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications. <i>Cancers</i> , 2021, 13, 1673.	3.7	21

#	ARTICLE	IF	CITATIONS
19	A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study. <i>Cancers</i> , 2021, 13, 2677.	3.7	6
20	Is the Strongest Level of Medical Evidence Always Required for Guidelines Recommendations?. <i>Liver Cancer</i> , 2021, 10, 1-2.	7.7	1
21	Recalibrating survival prediction among patients receiving transarterial chemoembolization for hepatocellular carcinoma. <i>Liver Cancer International</i> , 2021, 2, 45-53.	1.3	2
22	Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting. <i>Journal of Clinical Medicine</i> , 2021, 10, 3201.	2.4	13
23	Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.. <i>Digestive and Liver Disease</i> , 2021, 53, 1011-1019.	0.9	7
24	Time to move beyond the classical prognostic systems for patients with advanced hepatocellular carcinoma undergoing Sorafenib. <i>Digestive and Liver Disease</i> , 2021, 53, 1210-1211.	0.9	0
25	Clinical-Radiomic Analysis for Pretreatment Prediction of Objective Response to First Transarterial Chemoembolization in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 38-51.	7.7	58
26	The ITA.LI.CA Consortium: how multicentre collaboration helped shape the management of patients with hepatocellular carcinoma on the basis of real-world evidence.. <i>Annals of Hepatology</i> , 2021, , 100564.	1.5	1
27	Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment. <i>European Journal of Cancer</i> , 2021, 158, 133-143.	2.8	4
28	Beneficial Prognostic Effects of Aspirin in Patients Receiving Sorafenib for Hepatocellular Carcinoma: A Tale of Multiple Confounders. <i>Cancers</i> , 2021, 13, 6376.	3.7	13
29	Letter: is female sex really associated with better prognosis in hepatocellular carcinoma?. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 669-670.	3.7	1
30	Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?. <i>Vaccines</i> , 2020, 8, 578.	4.4	16
31	Prognostic Role of Bacterial and Fungal Infections in Patients With Liver Cirrhosis With and Without Acute-on-Chronic Liver Failure: A Prospective 2-Center Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa453.	0.9	7
32	Lusutrombopag Is Safe and Efficacious for Treatment of Thrombocytopenia in Patients With and Without Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2600-2608.e1.	4.4	7
33	Treatment of Hepatocellular Carcinoma in the Precision Medicine Era: From Treatment Stage Migration to Therapeutic Hierarchy. <i>Hepatology</i> , 2020, 72, 2206-2218.	7.3	107
34	Survival and Tolerability of Transarterial Chemoembolization in Greater Versus less than 70 Years of Age Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score Analysis. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 1015-1024.	2.0	6
35	Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. <i>Cancers</i> , 2019, 11, 1689.	3.7	44
36	Ramucirumab as a second-line treatment for hepatocellular carcinoma: reaching out further to patients with elevated alpha-fetoprotein. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 515-518.	1.5	1

#	ARTICLE	IF	CITATIONS
37	The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study. <i>Liver International</i> , 2019, 39, 1478-1489.	3.9	41
38	Long term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteria. <i>Scientific Reports</i> , 2019, 9, 3781.	3.3	18
39	Alpha-fetoprotein for Diagnosis, Prognosis, and Transplant Selection. <i>Seminars in Liver Disease</i> , 2019, 39, 163-177.	3.6	45
40	Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 296-304.	1.6	36
41	Development and Validation of a Scoring System That Includes Corrected QT Interval for Risk Analysis of Patients With Cirrhosis and Gastrointestinal Bleeding. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1388-1397.e1.	4.4	16
42	Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. <i>Journal of Hepatology</i> , 2019, 71, 265-273.	3.7	138
43	Patients with Barcelona Clinic Liver Cancer Stages B and C Hepatocellular Carcinoma: Time for a Subclassification. <i>Liver Cancer</i> , 2019, 8, 78-91.	7.7	53
44	Reply. <i>Hepatology</i> , 2019, 69, 465-466.	7.3	0
45	Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 859-871.	1.7	38
46	Response to Intermediate stage treatment: Is TACE enough?. <i>Liver International</i> , 2018, 38, 188-189.	3.9	1
47	Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients. <i>Digestive and Liver Disease</i> , 2018, 50, 156-162.	0.9	7
48	Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 403-414.	2.5	45
49	Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. <i>Hepatology</i> , 2018, 67, 1784-1796.	7.3	93
50	Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept. <i>Scientific Reports</i> , 2018, 8, 9997.	3.3	84
51	Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study. <i>Hepatology</i> , 2018, 68, 1232-1244.	7.3	26
52	Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis. <i>BMC Cancer</i> , 2018, 18, 715.	2.6	15
53	Metabolic disorders across hepatocellular carcinoma in Italy. <i>Liver International</i> , 2018, 38, 2028-2039.	3.9	10
54	Plasma cholesterol and lipoprotein levels in relation to tumor aggressiveness and survival in HCC patients. <i>International Journal of Biological Markers</i> , 2018, 33, 423-431.	1.8	23

#	ARTICLE	IF	CITATIONS
55	A meta-analysis of single <scp>HCV</scp>-untreated arm of studies evaluating outcomes after curative treatments of <scp>HCV</scp>-related hepatocellular carcinoma. Liver International, 2017, 37, 1157-1166.	3.9	70
56	Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. Journal of Hepatology, 2017, 67, 65-71.	3.7	83
57	Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment. Liver Cancer, 2017, 6, 16-26.	7.7	97
58	Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. Liver International, 2017, 37, 423-433.	3.9	46
59	The evolutionary scenario of hepatocellular carcinoma in Italy: an update. Liver International, 2017, 37, 259-270.	3.9	67
60	A Liver Index and its Relationship to Indices of HCC Aggressiveness. Journal of Integrative Oncology, 2016, 5, .	0.3	28
61	Osteonecrosis of the Jaw during Sorafenib Therapy for Hepatocellular Carcinoma. Tumori, 2016, 102, S69-S70.	1.1	26
62	Length time bias in surveillance for hepatocellular carcinoma and how to avoid it. Hepatology Research, 2016, 46, 1275-1280.	3.4	20
63	Lipiodol transarterial chemoembolization for hepatocellular carcinoma: Where are we now?. Hepatology, 2016, 64, 23-25.	7.3	19
64	Is it time to extend criteria for hepatic resection in the treatment of hepatocellular carcinoma?. Hepatology, 2016, 64, 2257-2258.	7.3	3
65	Ablation and resection for hepatocellular carcinoma within Milan criteria and high alpha-fetoprotein levels. Liver International, 2016, 36, 1877-1877.	3.9	1
66	Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study. British Journal of Cancer, 2016, 115, 297-302.	6.4	58
67	Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma. Digestive and Liver Disease, 2016, 48, 798-805.	0.9	46
68	Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma – The SHELTER study. Journal of Hepatology, 2016, 65, 280-288.	3.7	98
69	Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma. American Journal of Gastroenterology, 2016, 111, 70-77.	0.4	59
70	Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. PLoS Medicine, 2016, 13, e1002006.	8.4	113
71	Screening for Hepatocellular Carcinoma in Chronic Liver Disease. Annals of Internal Medicine, 2015, 162, 239.	3.9	2
72	Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor. Liver Transplantation, 2015, 21, 1250-1258.	2.4	10

#	ARTICLE	IF	CITATIONS
73	Efficacy of radioembolization according to tumor morphology and portal vein thrombosis in intermediate-advanced hepatocellular carcinoma. <i>Future Oncology</i> , 2015, 11, 3133-3142.	2.4	20
74	Prognosis of untreated hepatocellular carcinoma. <i>Hepatology</i> , 2015, 61, 184-190.	7.3	188
75	De novo hepatocellular carcinoma of liver allograft: A neglected issue. <i>Cancer Letters</i> , 2015, 357, 47-54.	7.2	27
76	BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. <i>Liver International</i> , 2015, 35, 223-231.	3.9	41
77	Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: A multicentre study. <i>Journal of Hepatology</i> , 2015, 62, 617-624.	3.7	184
78	Reply to: "Sorafenib or ⁹⁰ Y loaded resin microsphere radioembolization for locally advanced hepatocellular carcinoma, what should we trust?". <i>Liver International</i> , 2015, 35, 1780-1781.	3.9	2
79	Significance of Platelet and AFP Levels and Liver Function Parameters for HCC Size and Survival. <i>International Journal of Biological Markers</i> , 2014, 29, 215-223.	1.8	36
80	Improving survival of cirrhosis patients with hepatocellular carcinoma through application of standard of care. <i>Hepatology</i> , 2014, 60, 1446-1447.	7.3	5
81	Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014, 61, 333-341.	3.7	110
82	Factors That Affect Efficacy of Ultrasound Surveillance for Early Stage Hepatocellular Carcinoma in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1927-1933.e2.	4.4	108
83	Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: Implications for its clinical use. <i>Cancer</i> , 2014, 120, 2150-2157.	4.1	56
84	Accuracy of α -Fetoprotein Measurement in Detection of Hepatocellular Carcinoma: 1 More Nail in the Coffin. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 2138-2139.	4.4	2
85	Association of Abnormal Plasma Bilirubin With Aggressive Hepatocellular Carcinoma Phenotype. <i>Seminars in Oncology</i> , 2014, 41, 252-258.	2.2	40
86	Identification of Two Clinical Hepatocellular Carcinoma Patient Phenotypes From Results of Standard Screening Parameters. <i>Seminars in Oncology</i> , 2014, 41, 406-414.	2.2	14
87	Low Alpha-Fetoprotein HCC and the Role of GGTP. <i>International Journal of Biological Markers</i> , 2014, 29, 395-402.	1.8	21
88	Hepatocellular carcinoma in patients without cirrhosis in Italy. <i>Digestive and Liver Disease</i> , 2013, 45, 164-169.	0.9	38
89	Hepatocellular Carcinoma Responding to Superselective Transarterial Chemoembolization: An Issue of Nodule Dimension?. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 509-517.	0.5	95
90	Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2013, 45, 712-723.	0.9	155

#	ARTICLE	IF	CITATIONS
91	Outcome of hepatocellular carcinoma in human immunodeficiency virus-infected patients. Digestive and Liver Disease, 2013, 45, 516-522.	0.9	7
92	Surveillance for early diagnosis of hepatocellular carcinoma: How best to do it?. World Journal of Gastroenterology, 2013, 19, 8808.	3.3	72
93	Rise and fall of <sc>HCV</sc>-related hepatocellular carcinoma in Italy: a long-term survey from the <sc>ITA</sc>.<sc>LI</sc>.<sc>CA</sc> centres. Liver International, 2013, 33, 1420-1427.	3.9	13
94	Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. Liver International, 2013, 33, 1594-1600.	3.9	46
95	Surveillance for Hepatocellular Carcinoma: Just Do It!. American Journal of Gastroenterology, 2013, 108, 1013-1014.	0.4	5
96	Metronomic Capecitabine in Advanced Hepatocellular Carcinoma Patients: A Phase II Study. Oncologist, 2013, 18, 1256-1257.	3.7	64
97	Ten-Year Outcome of Radiofrequency Thermal Ablation for Hepatocellular Carcinoma: An Italian Experience. American Journal of Gastroenterology, 2012, 107, 1588-1589.	0.4	6
98	Effectiveness of α -fetoprotein for hepatocellular carcinoma surveillance: the return of the living-dead?. Expert Review of Gastroenterology and Hepatology, 2012, 6, 441-444.	3.0	13
99	Liver transplantation for hepatocellular carcinoma in clinical practice. European Journal of Gastroenterology and Hepatology, 2012, 24, 195-202.	1.6	15
100	<sc>QT</sc> interval prolongation by acute gastrointestinal bleeding in patients with cirrhosis. Liver International, 2012, 32, 1510-1515.	3.9	48
101	The changing scenario of hepatocellular carcinoma over the last two decades in Italy. Journal of Hepatology, 2012, 56, 397-405.	3.7	84
102	Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population. Journal of Hepatology, 2012, 56, 1089-1096.	3.7	61
103	Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. Hepatology, 2012, 56, 1371-1379.	7.3	130
104	Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance. Digestive and Liver Disease, 2011, 43, 875-80.	0.9	23
105	Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. Lancet Oncology, The, 2011, 12, 654-662.	10.7	135
106	Relative decrease in the role played by hepatitis B virus infection in the aetiology of hepatocellular carcinoma during a 20-year period: a multicentre Italian study. Liver International, 2011, 31, 192-196.	3.9	8
107	Alpha-fetoprotein in hepatocellular carcinoma surveillance: Wake not the dead. Hepatology, 2011, 54, 376-377.	7.3	10
108	Transarterial chemoembolization in Child-Pugh class B patients with hepatocellular carcinoma: between the devil and the deep blue sea. Liver International, 2010, 30, 923-924.	3.9	5

#	ARTICLE	IF	CITATIONS
109	Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience. <i>Gut</i> , 2010, 59, 387-396.	12.1	145
110	Art in the Hospital: Its Impact on the Feelings and Emotional State of Patients Admitted to an Internal Medicine Unit. <i>Journal of Alternative and Complementary Medicine</i> , 2010, 16, 853-859.	2.1	13
111	Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. <i>Journal of Hepatology</i> , 2010, 53, 291-297.	3.7	281
112	Hepatocellular carcinoma in non-cirrhotic liver: A reappraisal. <i>Digestive and Liver Disease</i> , 2010, 42, 341-347.	0.9	155
113	Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study. <i>BMC Cancer</i> , 2009, 9, 33.	2.6	79
114	Prognostication of the outcome of hepatocellular carcinoma: How to rely on science instead of on the art of Nostradamus. <i>Digestive and Liver Disease</i> , 2009, 41, 382-384.	0.9	4
115	Hepatocellular Carcinoma in Patients With Cryptogenic Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 580-585.	4.4	48
116	Is female sex a significant favorable prognostic factor in hepatocellular carcinoma?. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 1212-1218.	1.6	51
117	Effect of chronic β^2 -blockade on QT interval in patients with liver cirrhosis. <i>Journal of Hepatology</i> , 2008, 48, 415-421.	3.7	83
118	Surveillance for Early Diagnosis of Hepatocellular Carcinoma: Is It Effective in Intermediate/Advanced Cirrhosis?. <i>American Journal of Gastroenterology</i> , 2007, 102, 2448-2457.	0.4	110
119	Impact of Etiology of Cirrhosis on the Survival of Patients Diagnosed With Hepatocellular Carcinoma During Surveillance. <i>CME. American Journal of Gastroenterology</i> , 2007, 102, 1022-1031.	0.4	54
120	Daily profile of circulating C-type natriuretic peptide in pre-ascitic cirrhosis and in normal subjects: Relationship with renal function. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 642-647.	1.5	7
121	QT Interval Correction in Patients with Cirrhosis. <i>Journal of Cardiovascular Electrophysiology</i> , 2007, 18, 77-82.	1.7	67
122	Prevalence and Prognostic Significance of the Presence of Esophageal Varices in Patients With Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1378-1384.	4.4	69
123	Effect of the Etiology of Viral Cirrhosis on the Survival of Patients with Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2006, 101, 91-98.	0.4	81
124	Diagnostic and Prognostic Role of alpha-Fetoprotein in Hepatocellular Carcinoma: Both or Neither?. <i>American Journal of Gastroenterology</i> , 2006, 101, 524-532.	0.4	391
125	Cardiac electrophysiological abnormalities in patients with cirrhosis. <i>Journal of Hepatology</i> , 2006, 44, 994-1002.	3.7	141
126	Surveillance for Hepatocellular Carcinoma in Elderly Italian Patients With Cirrhosis: Effects on Cancer Staging and Patient Survival. <i>American Journal of Gastroenterology</i> , 2004, 99, 1470-1476.	0.4	116

#	ARTICLE	IF	CITATIONS
127	Systemic and regional hemodynamics in pre-ascitic cirrhosis: effects of posture. Journal of Hepatology, 2003, 39, 502-508.	3.7	20
128	Semiannual and Annual Surveillance of Cirrhotic Patients for Hepatocellular Carcinoma: Effects on Cancer Stage and Patient Survival (Italian Experience). American Journal of Gastroenterology, 2002, 97, 734-744.	0.4	282
129	Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Meta-Analysis of Randomized Controlled Trials. Radiology, 2002, 224, 47-54.	7.3	784
130	Serum α -fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. Journal of Hepatology, 2001, 34, 570-575.	3.7	677
131	Q-T interval prolongation in cirrhosis: Prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology, 1998, 27, 28-34.	7.3	356
132	Etiologic factors and clinical presentation of hepatocellular carcinoma. Differences between cirrhotic and noncirrhotic Italian patient. Cancer, 1995, 75, 2220-2232.	4.1	155
133	Prognostic indicators in patients with cirrhosis and hepatocellular carcinoma undergoing surgical resection. Journal of Surgical Oncology, 1993, 53, 67-69.	1.7	6
134	Renal sodium retention during upright posture in preascitic cirrhosis. Gastroenterology, 1993, 105, 188-193.	1.3	95
135	The hemodynamic status of preascitic cirrhosis: An evaluation under steady-state conditions and after postural change. Hepatology, 1992, 16, 341-346.	7.3	87